European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2198 participants.
Also called NCT01087723
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,198 participants
- Sponsor
- Registry
-
NCT01087723
-
- Other papers using this trial's data
- Bivalirudin started during emergency transport for primary PCI
- Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial
- Impact of arterial access site on outcomes after primary percutaneous coronary intervention: prespecified subgroup analysis from the EUROMAX trial
- One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Austria, Czechia, Denmark, France, Germany, Italy, Netherlands, Poland, Slovenia
- Registry status
- Completed
Technical summary
Registry record NCT01087723. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2013-08 (actual). Results posted on 2016-02-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
- Acronym
- EUROMAX
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Bivalirudin
- Intervention (Drug)
- Heparin
- Lead sponsor
- The Medicines Company
Record details
- Record id
cardio:ct-nct01087723- Content hash
c7d3222d4ecb5b057bbaf58501ea784220960e6422ca5c0b56b3028be1f0f731